Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design - Wikidata - wikimedia - TriplyDB

Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

http://www.wikidata.org/entity/Q33817568

about

A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues Pathogenesis of Focal Segmental Glomerulosclerosis Moxibustion Alleviates Injury in a Rat Focal Segmental Glomerulosclerosis Model.Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations.Therapeutic targets for treating fibrotic kidney diseases Nephrotic syndrome in children: from bench to treatment Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.Circulating suPAR in two cohorts of primary FSGS.Serum glomerular albumin permeability activity: association with rapid progression to end-stage renal disease in focal segmental glomerulosclerosis.Drugs and trials: lessons from Plato.Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.The glomerular permeability factors in idiopathic nephrotic syndrome.Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology.Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury.Effect of immunosuppression on the human mesangial cell cycle.Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease.Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

P2860

Q26776389-FD4B19A5-03A9-45C8-B66B-7C476B7626EA Q28067299-98C5E94C-C364-4024-904F-8AF1A71F9813 Q33786923-11FC9938-4CC3-4698-8F24-7E9BD9F9A8A0 Q34556394-DBE71785-7A16-4DF1-B38C-F0AB275AB79E Q35079607-8C890AF9-EBB7-4CCB-BE49-6D09FDA7AA0F Q35185376-EA086110-337D-44BB-BB84-8B36AA970328 Q35704498-B67A26BF-09C0-4CD7-97C4-72B65ED80D95 Q36426091-A89E78D5-254B-4005-ADE4-066A7173D230 Q36789030-B54C5450-1DC4-4C56-B3AE-B19D12E8AC32 Q37174765-17D51BF5-C9F4-47C3-BD79-260B2F52C124 Q37928188-7B10541B-A0C7-40F9-8AFB-7FC4D69BB857 Q38449629-1381B5AA-7E68-4950-963B-D86EE5CA0824 Q38991259-ECC1FA16-A97D-42BB-B0BB-2C3885A35D69 Q41559116-48748BA7-5AE9-4CC8-B03D-C7B33D1EE622 Q42563694-AE95D6BA-4362-4F29-816A-3300AD8F2E49 Q50867897-5121708C-0631-4766-83C1-CF43A22F61C5 Q53497916-9104A21B-15C5-4E7A-A407-0F6E4B90E114

P2860

Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

http://www.wikidata.org/entity/Q33817568

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Novel therapies for resistant ...... I clinical trial: study design

@ast

Novel therapies for resistant ...... I clinical trial: study design

@en

type

label

Novel therapies for resistant ...... I clinical trial: study design

@ast

Novel therapies for resistant ...... I clinical trial: study design

@en

prefLabel

Novel therapies for resistant ...... I clinical trial: study design

@ast

Novel therapies for resistant ...... I clinical trial: study design

@en

P1433

Q33817568-5AC27FC9-96BE-4781-9F5E-2A2BEDBDCF9C

P1476

Q33817568-EA28DF48-84D4-47E7-AFFC-0794A25F872E

P2093

Q33817568-18F22107-6D62-4D4B-B848-BFC591FF6564

Q33817568-33181A21-B3CA-45BE-80FE-7C461769FCC3

Q33817568-51A43E13-8A26-4DE3-AF7B-7DA5BEAC498C

Q33817568-94D596D2-4E11-427B-BFA7-C14644C36D0E

Q33817568-BDDDFB16-228D-4B2B-A853-20DD5B922216

Q33817568-D7E7059C-590F-409B-886F-9F2C8C519E8F

Q33817568-E18D9562-2F09-49AE-A3E6-78F85B97E11D

P2860

Q33817568-021E85D3-5602-4886-A7ED-F5528FB3A198

Q33817568-12D9ADB9-5C75-4EAE-92F2-3743A124857D

Q33817568-1B2B7B9F-51F6-413D-9C51-A57E215ACB42

Q33817568-2486DF77-E6DA-4974-8BF9-501CB0A7BD91

Q33817568-257834C5-FC99-4EC1-9E29-62F90AC71F35

Q33817568-25C65513-C982-41D8-98A6-D2EA3EFF3FB1

Q33817568-2C366F7E-930B-4F78-A263-993C246E503E

Q33817568-36E9FC1A-F887-4007-803C-92768130D253

Q33817568-3A123FC4-B3B0-43BB-A7AE-E2F2F790BE83

Q33817568-3D596565-B460-413F-BC13-4646F340A8FB

P2888

Q33817568-8C1F602E-8393-4586-99E7-77B74874848F

P304

Q33817568-1A754FE5-5771-43D0-B8A0-DC378EAF17E1

P31

Q33817568-741D0474-74AB-4ACC-BA80-3EEB1D462D04

P356

Q33817568-B67B4B2F-4091-4503-8588-7ED2612DEA24

P478

Q33817568-2F377078-0740-4E9A-978D-43B02A1987CB

P50

Q33817568-272838A0-A808-4A3C-BF08-3F53EF9236BB

Q33817568-28D46C3B-E273-4447-8611-4033BF3857AD

Q33817568-76841AB7-1532-49D0-B225-1EF85522A88A

Q33817568-C1A55329-9739-441C-B220-4E5BF24F2D98

P577

Q33817568-60245FDE-ABE7-4033-AC00-3BD4B2937D80

P5875

Q33817568-3128920B-0628-4F17-A644-355CAC9D7489

P6179

Q33817568-F2E98CB0-C1A0-4E3B-9624-AC84FE5C5094

P698

Q33817568-967C2F9B-E907-4DA0-BE1B-F1C2D8634D55

P921

Q33817568-35137FAB-8180-462D-86A3-12DB68ECF827

P932

Q33817568-B6D6A131-9CA5-4E76-A419-43ED1B7DAED1

P356

P1433

P1476

Novel therapies for resistant ...... I clinical trial: study design

@en

P2093

Jennifer Gassman

http://www.w3.org/2001/XMLSchema#string

Larysa Wickman

http://www.w3.org/2001/XMLSchema#string

Melanie Joy

http://www.w3.org/2001/XMLSchema#string

Michael Somers

http://www.w3.org/2001/XMLSchema#string

Suzanne Vento

http://www.w3.org/2001/XMLSchema#string

Tom Greene

http://www.w3.org/2001/XMLSchema#string

Virginia Savin

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group

Management of focal segmental glomerulosclerosis: evidence-based recommendations.

Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis.

Renoprotection: one or many therapies?

Broadening the spectrum of diseases related to podocin mutations.

Regulation of proliferation, survival and apoptosis by members of the TNF superfamily.

P2888

P304

8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2369-12-8

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Howard Trachtman

Debbie S Gipson

Jennifer Gassman

P577

2011-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49825647

http://www.w3.org/2001/XMLSchema#string

P6179

1038031954

http://www.w3.org/2001/XMLSchema#string

P698

21310077

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3045306

http://www.w3.org/2001/XMLSchema#string